Test Code FNEOS Neopterin
Specimen Required
Specimen Type: Serum
Container/Tube: Red or SST
Specimen Volume: 0.8 mL
Collection Instructions: Draw blood in a plain red-top tube(s), serum gel tube(s) is acceptable. Spin down and send 0.8 mL serum light protected in a screw-capped vial (Supply T915 amber vial), shipped frozen.
Secondary ID
75451Useful For
Increased levels of neopterin are found during impaired renal function and viral infection in transplant patients. Elevated levels are also indicators for conditions related to impaired cellular immunity.
Method Name
Enzyme immunoassay (EIA)
Reporting Name
Neopterin, SerumSpecimen Type
SerumSpecimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Frozen (preferred) | 180 days | LIGHT PROTECTED |
| Refrigerated | 72 hours | LIGHT PROTECTED |
Reject Due To
| Hemolysis | Mild OK; Gross Reject |
| Lipemia | Mild OK; Gross Reject |
| Icterus | Mild OK; Gross Reject |
| Other | Not light protected specimens |
Clinical Information
Neopterin, a pyrazolopyridine compound, is produced by macrophages after induction by interferon ? and serves as a marker of cellular immune system activation. Measurable levels of neopterin have been detected in both the serum and urine of patients suffering from various types of malignancies and viral infections. Changes in neopterin concentrations in serum or urine can predict complications such as graft rejection in organ transplant recipients. Elevated neopterin levels are found in autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus (SLE). Neopterin levels can be used as prognostic predictors for certain types of malignancies. Measurement of neopterin levels has particular value for monitoring patients infected with HIV. Neopterin is eliminated primarily in the urine, so evaluation of urinary neopterin levels may be useful in assessing activation of the cellular immunity system even in the absence of typical clinical symptoms, since a correlation has been observed with the course of diseases involving cellular immunity activation and urinary neopterin levels.
Reference Values
Adults: <2.5 ng/mL
Clinical Reference
Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type I. N Engl J Med. 1990 Jan; 322(3):166-172
Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H. Neopterin as a marker for activated cell-mediated immunity: Application in HIV infection. Immunol Today. 1988 May; 9(5):150-155
Jacobson MA, Bacchetti P, Kolokathis A, et al. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. BMJ. 1991 Jan 12; 302(6768):73-78
Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as a marker for activation of cellular immunity: Immunologic basis and clinical application. Adv Clin Chem. 1989; 27:81-141
Day(s) Performed
Monday
Report Available
1 to 12 daysPerforming Laboratory
LabCorp BurlingtonCPT Code Information
83520
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| FNEOS | Neopterin, Serum | 34908-4 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| FNEOS | Neopterin, Serum | 34908-4 |